Kelle, İlkerEriman, H.Erdi̇nç, Meral AlperUyar, Emre2023-03-222023-03-222022Kelle, İ., Eriman, H., Erdinc, M. ve Uyar, E. (2022). Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice. European Review for Medical and Pharmacological Sciences, 26(5), 1708-1716.1128-3602https://hdl.handle.net/11468/11478OBJECTIVE: Ketamine, an N-methyl D-aspartic acid receptor antagonist drug, is reported to produce memory disruptions. The aim of this study was to investigate the protective effects of ethyl pyruvate (EP), a pyruvic acid derivative, and risperidone, an atypical anti-psychotic drug, against ketamine-induced cognitive disturbances. MATERIALS AND METHODS: A passive-avoidance test, a novel object recognition test, and a modified elevated plus maze test were used to assess memory functions. Hippocampal malondialdehyde (MDA) levels were measured to determine the oxidation levels. RESULTS: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments. CONCLUSIONS: Increased oxidative stress and neurotransmission imbalance can be responsible for ketamine-induced memory disruptions. With its antioxidant effects, EP may be helpful to reduce cognitive impairments related to schizophrenia either alone or in combination with antipsychotics.eninfo:eu-repo/semantics/closedAccessEthyl pyruvateRisperidoneKetamineSchizophreniaCognitive symptomsArticle26517081716WOS:000771549500037ScopusIdYok35302220Q2Q2